2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Neonatal
PAPER

2879 Sutimlimab as rescue therapy for treating severe/refractory cold agglutinin disease or syndrome : An observational study on the french experience

Kevin Chevalier, MD, MSc, Lionel Galicier2, Pauline Durand3, Mikael Ebbo4, Corinne Haioun Sr, MD, PhD5, Paul Legendre6, Thomas Moulinet7, Adrien Robine8, Caroline Soubrier9, Louis Terriou10, Yoann Zadro11, Guillaume Moulis12, Marc Michel, MSc13
1 Hôpitaux Universitaires Henri Mondor, Créteil, France
2 La Timone Marseille, Marseille, France
3 Hôpital Robert Boulin, Libourne, France
4 La Timone Marseille, Marseille, France
5 Hôpitaux Universitaires Henri Mondor, Créteil, France
6 Centre Hospitalier du Mans, Le Mans, France
7 CHRU de Nancy, Nancy, France
8 Centre Hospitalier de Bourg-en-Bresse, Viriat, France
9 Centre Hospitalier Notre-Dame de la Miséricorde, Ajaccio, France
10 Centre Hospitalier Régional Universitaire de Lille, Lille, France
11 Toulouse University Purpan Hospital Heliport, Toulouse, France
12 Toulouse University Purpan Hospital Heliport, Toulouse, France
13 Hôpitaux Universitaires Henri Mondor, Créteil, France

Background: Cold agglutinin disease (CAD) or syndrome (CAS) encompass a rare, complement-mediated autoimmune hemolytic anemia (AIHA) driven by cold-reactive IgM autoantibodies that activate the classical complement pathway via C1s, causing chronic hemolysis with sometimes acute exacerbations leading to severe hemolytic anemia requiring a prompt management. Sutimlimab, a humanized monoclonal anti-C1s antibody, is approved for CAD, but real-world data on its use as rescue therapy in patients with severe and/or refractory disease remain limited, particularly outside the setting of pivotal clinical trials.

 

Methods: We analyzed patients included in the CARMEN-France registry, a French nationwide, multicenter registry of AIHA, with a diagnosis of CAD or CAS (all with a positive direct antiglobulin test [DAT] with a C3d pattern and the presence of CA at titer ≥ 1/64) who received sutimlimab as rescue therapy after failure of prior treatment-lines, up to July 2026. Baseline characteristics, disease history, clinical and biological findings at sutimlimab initiation, and hematologic response were collected. Response to treatment (R) was defined as a stable hemoglobin (Hb) level increase above 10 g/dL with an increase of at least 2 g/dL  in the absence of concomittant transfusion, and partial response (PR) as a Hb level ≤ 10 g/dl with an increase of at least 2 g/dL  from baseline in the absence of concomittant transfusion.

 

Results: Nine patients were included. Median age at diagnosis was 65 years [interquartile range (IQR), 60-73], and 7 patients (77.8%) were female; 3 patients (33.3%) had CAS. Median hemoglobin at diagnosis was 5.7 g/dL [4.5-8.6], with a nadir of 5.0 g/dL [4.0-6.8]; all patients required transfusion (median 8 red blood cell units/patient [6-11]). Patients were heavily pretreated, with a median of 3 prior treatment lines [2-3], including recombinant erythropoietin (n=9, 100%), corticosteroids (n=4, 44.4%), rituximab (n=7, 77.8%), bendamustine (n=2, 22.2%), ibrutinib (n=2, 22.2%), zanubrutinib (n=2, 22.2%), and venetoclax (n=1, 11.1%). Complete response was achieved only with rituximab, in 2 out of 7 patients (28.6%).

At sutimlimab initiation, all patients were symptomatic, with jaundice (n=5, 55.6%), dark urine (n=4, 44.4%), heart failure (n=2, 22.2%), and fever/chills (n=1, 11.1%). Median Hb was 8.3 g/dL [7.0-8.8], lactate dehydrogenase 456 IU/L [350-604], haptoglobin 0.1 g/dL [0-0.1], and total bilirubin 33 µmol/L [23-52]. Patients received a median of 3 [2-6] sutimlimab infusions, with a response achieved in 6 patients (66.6%) after a median of 18 [13-41] days. None of the 3 remaining patients achieved PR, including one who received only a single infusion and two who received 3 infusions each. Two patients (22.2%) experienced serious infections: one developed cholangitis with Acinetobacter ursingiibacteremia and Candida parapsilosis fungemia, and the other an influenza A virus severe infection. No other side-effects or deaths were recorded.

 

Conclusion: In this real-world small cohort of heavily pretreated patients with severe CAD/CAS, sutimlimab used as rescue therapy was successful in two-thirds of patients within a median of 18 days, confirming its efficacy after failure of multiple prior treatment lines, including rituximab and other B-cell-targeted agents. One-third of patients did not respond, underscoring the need to identifying predictors of response.

Kevin Chevalier, MD, MSc: No relevant conflicts of interest to declare.